The therapeutic potential of GLP-1 receptor modulation is evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4 protocols. These clinical investigations primarily target type 2 diabetes mellitus, post-pancreatectomy hyperglycemia, hypertriglyceridemia-induced acute pancreatitis, and obesity management in overweight individuals. Research initiatives are spearheaded by a mix of academic medical centers and university hospitals, such as Peking Union Medical College Hospital, University Hospital Gentofte, and the University of California, San Francisco. Recruitment statuses across the trial landscape encompass completed protocols, such as NCT00822705 and NCT06895408, alongside actively recruiting and upcoming studies focused on postprandial glucose regulation and disease prevention.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07462663 | NOT_YET_RECRUITING | Endometrial Cancer; Endometrial Cancer Stage I; Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I; Atypical Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Obesity & Overweight; BMI>40; Obesity; Obesity Grade III |
Hospital Universitari de Bellvitge |
2027-01 | PHASE4 |
| NCT06977438 | NOT_YET_RECRUITING | Obesity, Childhood |
University of Minnesota |
2026-10-01 | PHASE4 |
| NCT07282041 | RECRUITING | Intracranial Atherosclerosis; Stroke, Ischemic |
National University of Singapore |
2025-12-17 | PHASE2; PHASE3 |
| NCT07527910 | RECRUITING | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
Regeneron Pharmaceuticals |
2026-05-22 | PHASE2 |
| NCT07178145 | RECRUITING | Heart Failure Preserved Ejection Fraction; Epicardial Adipose Tissue |
University of Virginia |
2025-11-20 | PHASE4 |
| NCT06582875 | RECRUITING | Autosomal Dominant Polycystic Kidney; Obesity |
University of Colorado, Denver |
2025-03-06 | PHASE2 |
| NCT07736911 | RECRUITING | GLP-1 |
Fu Jen Catholic University Hospital |
2026-06-01 | PHASE3 |
| NCT05390892 | RECRUITING | Type2Diabetes; ASCVD |
Brigham and Women's Hospital |
2022-09-26 | PHASE4 |
| NCT06972407 | NOT_YET_RECRUITING | Genetic Predisposition; Type2diabetes |
Mayo Clinic |
2026-10-01 | PHASE2 |
| NCT07687667 | NOT_YET_RECRUITING | Polycystic Ovary Syndrome (PCOS); Obesity; Infertility, Female |
Peking University Third Hospital |
2026-07 | |
| NCT07107334 | RECRUITING | Endometrioid Endometrial Adenocarcinoma |
University of Florida |
2026-04-07 | PHASE2 |
| NCT06976619 | RECRUITING | Type 1 Diabetes; Type 2 Diabetes |
Mayo Clinic |
2025-10-03 | PHASE2 |
| NCT07737522 | NOT_YET_RECRUITING | Pulmonary Arterial Hypertension |
Imperial College London |
2026-10-01 | PHASE2 |
| NCT07617155 | NOT_YET_RECRUITING | Hypertriglyceridemia Induced Acute Pancreatitis; Recurrent Acute Pancreatitis; Pancreatitis Relapsing; Hypertriglyceridemia |
Peking Union Medical College Hospital |
2026-09 | PHASE4 |
| NCT07784127 | NOT_YET_RECRUITING | Diabetes |
The Cleveland Clinic |
2026-12 | |
| NCT07249554 | NOT_YET_RECRUITING | Alcohol Use Disorder |
Johns Hopkins University |
2026-09 | PHASE2 |
| NCT06132477 | RECRUITING | Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension; Obstructive Sleep Apnea of Adult |
University of Missouri-Columbia |
2024-02-01 | PHASE4 |
| NCT07613437 | NOT_YET_RECRUITING | Intracerebral Hemorrhage |
Chinese University of Hong Kong |
2026-06-15 | PHASE2 |
| NCT07755085 | NOT_YET_RECRUITING | Arthritis; Obesity & Overweight; GLP - 1 |
Nova Scotia Health Authority |
2026-10-01 | PHASE4 |
| NCT07676331 | NOT_YET_RECRUITING | Hormone-receptor-positive Breast Cancer; Early Breast Cancer |
Universitaire Ziekenhuizen KU Leuven |
2026-08-01 | PHASE2 |
| NCT07732426 | RECRUITING | Food Addiction Tendency; Obesity; Overweight |
Seoul National University Hospital |
2026-07-15 | |
| NCT07117240 | ENROLLING_BY_INVITATION | Steroid-Induced Diabetes; Steroid-Induced Hyperglycemia; Diabetes |
Medical University of Warsaw |
2025-07-10 | PHASE4 |
| NCT07387796 | RECRUITING | Drug Discontinuation; Substance Use Disorders; Eating Behavior Changes; Tirzepatide |
The University of Texas at Dallas |
2026-10 | |
| NCT07621640 | NOT_YET_RECRUITING | Obesity; Metabolic Syndrome; Brown Adipose Tissue |
Hallym University |
2026-06 | |
| NCT07614412 | NOT_YET_RECRUITING | Type 1 Diabetes Mellitus |
Ministry of Health, Saudi Arabia |
2027-01-01 | PHASE2 |
| NCT07789106 | NOT_YET_RECRUITING | Obesity & Overweight; GLP - 1; Fatigue Severity Scale; Ubiquinol; Muscle Contraction |
StudySetGo |
2026-09-01 | |
| NCT07244458 | RECRUITING | Dietary Change; Obesity & Overweight; Food Acceptance |
Ian J. Neeland, MD |
2026-04-20 | |
| NCT06751589 | RECRUITING | Endometrial Cancer |
Memorial Sloan Kettering Cancer Center |
2024-12-19 | EARLY_PHASE1 |
| NCT07224334 | RECRUITING | Diabetes (DM) |
David D'Alessio, M.D. |
2025-12-30 | PHASE1 |
| NCT07336862 | RECRUITING | Obesity |
China-Japan Friendship Hospital |
2024-01-01 | PHASE1; PHASE2 |
| NCT06682351 | NOT_YET_RECRUITING | Prediabetes / Type 2 Diabetes |
Stanford University |
2024-11 | PHASE4 |
| NCT07607587 | RECRUITING | Obesity; Overweight |
Novo Nordisk A/S |
2026-05-29 | PHASE1 |
| NCT07136714 | RECRUITING | Major Depressive Disorder |
Nordsjaellands Hospital |
2025-09-11 | PHASE4 |
| NCT07756359 | NOT_YET_RECRUITING | Pouch, Ileal; Pouches, Ileoanal; Bowel Diseases, Inflammatory |
University of North Carolina, Chapel Hill |
2026-09 | PHASE4 |
| NCT06487832 | RECRUITING | Normal Weight; Overweight and Obesity; Insulin Sensitivity; Insulin Resistance |
University Hospital Tuebingen |
2024-07-01 | |
| NCT07787533 | NOT_YET_RECRUITING | Women's Health; Obesity & Overweight; Perimenopausal Women; Digital Intervention; Behavior Change; glp1 Agonist; Resistance Exercise |
Louisiana State University and A&M College |
2026-11-01 | |
| NCT07736963 | RECRUITING | GLP-1 |
Fu Jen Catholic University Hospital |
2026-06-01 | |
| NCT06318442 | RECRUITING | Steroid-Induced Diabetes; Steroid Induced Hyperglycemia |
Imperial College London |
2024-05-15 | |
| NCT07411378 | NOT_YET_RECRUITING | Muscle Wasting; Obesity & Overweight; Obesity |
Biophytis |
2026-07 | PHASE2 |
| NCT07625202 | RECRUITING | Sarcopenia |
University of Saskatchewan |
2026-05-25 | |
| NCT07652333 | RECRUITING | Muscle Composition; Obesity; Quality of Life (QOL) |
University of Pittsburgh |
2026-05-25 | |
| NCT06548490 | RECRUITING | Opioid Use Disorder; Opioid Abuse and Addiction; Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorder; Opioid |
Milton S. Hershey Medical Center |
2025-01-27 | PHASE2 |
| NCT05071898 | RECRUITING | Obesity; Diabetes Type 2 |
University of Maryland, Baltimore |
2022-04-11 | PHASE1 |
| NCT07293325 | RECRUITING | Adults With Simple Obesity |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-06-02 | |
| NCT07518407 | ACTIVE_NOT_RECRUITING | Obesity Type 2 Diabetes Mellitus; Obesity |
University of South Carolina |
2026-04-06 | |
| NCT07234916 | ENROLLING_BY_INVITATION | Weight Loss; Nutritional Deficiencies; GLP - 1; Obese Patients |
Erasmus Medical Center |
2025-12-16 | |
| NCT07758231 | NOT_YET_RECRUITING | GLP-1; Alcohol |
University of Wisconsin, Madison |
2026-10 | PHASE1 |
| NCT06338553 | RECRUITING | Type 1 Diabetes |
Vanderbilt University Medical Center |
2024-06-12 | EARLY_PHASE1 |
| NCT07251556 | NOT_YET_RECRUITING | Psoriasis Arthritis |
Chinese University of Hong Kong |
2025-12-01 | PHASE4 |
| NCT06546384 | NOT_YET_RECRUITING | Adiposity; Fatty Liver; Alcohol Use Disorder |
Insel Gruppe AG, University Hospital Bern |
2026-11-01 | |
| NCT06654219 | RECRUITING | Pulmonary Aspiration |
The University of Texas Health Science Center, Houston |
2025-10-30 | |
| NCT07225816 | RECRUITING | Obesity |
Novo Nordisk A/S |
2025-11-07 | PHASE1 |
| NCT07104539 | RECRUITING | Muscle Mass |
Virginia Polytechnic Institute and State University |
2025-10-08 | |
| NCT07393360 | RECRUITING | Obesity & Overweight |
Pharmanutra S.p.a. |
2025-12-11 | |
| NCT01851694 | RECRUITING | Cystic Fibrosis; Pancreatic Insufficiency |
University of Pennsylvania |
2013-05 | |
| NCT07431086 | ACTIVE_NOT_RECRUITING | Overweight or Obesity |
Regeneron Pharmaceuticals |
2026-03-16 | PHASE2 |
| NCT07728669 | RECRUITING | Type 2 Diabetes Mellitus (T2DM); Obesity (Disorder); Overweight; Metabolic Syndrome |
Kazakh Academy of Nutrition |
2026-07-20 | |
| NCT07484061 | RECRUITING | Telogen Effluvium |
Olistic Research Labs S.L. |
2026-03-16 | |
| NCT07179120 | NOT_YET_RECRUITING | Obesity-related Male Infertility |
First Affiliated Hospital of Wenzhou Medical University |
2026-05-01 | PHASE2 |
| NCT07595575 | NOT_YET_RECRUITING | The Whole-body Protein Synthesis Response to Protein With Amino Acid or Amino Acids |
Nutraceutical Innovations LLC |
2026-06-01 | |
| NCT07127354 | RECRUITING | GLP - 1; Bowel Preparation for Colonoscopy |
The Cleveland Clinic |
2025-08-01 | PHASE4 |
| NCT07437911 | RECRUITING | Nutrition Intake; Nutrition Status; Gastrointestinal Microbiome; GLP-1 |
Athletic Greens International |
2026-02 | |
| NCT07572513 | RECRUITING | Blood Glucose; GLP-1; Satiety; Second Meal Intake; Healthy Participant Study |
Purdue University |
2026-05-01 | |
| NCT07209046 | NOT_YET_RECRUITING | Adults; GLP-1 |
Metagenics, Inc. |
2025-11-01 | |
| NCT07554417 | NOT_YET_RECRUITING | GLP - 1; Obesity & Overweight; Muscle Loss; Exercise Intervention; Dietary Assessment |
William Marsh Rice University |
2026-04-06 | PHASE4 |
| NCT07055386 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
Gan & Lee Pharmaceuticals. |
2025-08-07 | PHASE2 |
| NCT06716424 | COMPLETED | Type 2 Diabetes |
Sanofi |
2025-01-06 | PHASE4 |
| NCT06851858 | ACTIVE_NOT_RECRUITING | Endocrinology; Diabetes, Type II; Obesity |
AstraZeneca |
2025-03-12 | PHASE2 |
| NCT07297238 | COMPLETED | Short Bowel Syndrome (SBS); Intestinal Failure |
Jinling Hospital, China |
2026-01-24 | |
| NCT07744360 | COMPLETED | GI Symptoms |
Olipop, PBC |
2026-02-10 | |
| NCT07089732 | NOT_YET_RECRUITING | Obesity; Prediabetes |
Chung Shan Medical University |
2025-08-08 | |
| NCT07140055 | NOT_YET_RECRUITING | Normal Healthy Volunteer; Safety After Oral Intake |
Biolexis Therapeutics |
2025-09 | PHASE1 |
| NCT07130396 | NOT_YET_RECRUITING | GLP-1; Adults |
Metagenics, Inc. |
2025-11-01 | |
| NCT06790771 | COMPLETED | Hunger |
Texas Christian University |
2025-01-15 | |
| NCT07194317 | COMPLETED | Obese Patients |
King's College London |
2025-09-01 | |
| NCT06605703 | COMPLETED | Obesity; Overweight |
WW International Inc |
2024-09-18 | PHASE4 |
| NCT06513715 | UNKNOWN | Obesity; Overweight |
Universidad Católica San Antonio de Murcia |
2024-01-09 | |
| NCT07210684 | RECRUITING | Prediabetes |
Nanjing Nutrabuilding Bio-tech Co., Ltd. |
2025-08-06 | |
| NCT05569304 | UNKNOWN | Obesity |
Sengkang General Hospital |
2022-10-07 | |
| NCT07703865 | COMPLETED | Obesity & Overweight; Gut -Microbiota |
University of Muhammadiyah Jakarta |
2025-09-15 | |
| NCT06194955 | COMPLETED | Incretin Effect |
University of Copenhagen |
2023-01-04 | |
| NCT07082062 | RECRUITING | Overweight |
Shih Chien Huang |
2025-06-02 | |
| NCT07280403 | COMPLETED | Weight Loss |
INQUIS Clinical Research |
2024-09-12 | |
| NCT04466566 | COMPLETED | Healthy |
Adrian Vella |
2022-10-17 | PHASE3 |
| NCT07103083 | RECRUITING | Blood Glucose; Blood Insulin |
Ocean Spray Cranberries, Inc. |
2025-07-21 | |
| NCT06789263 | COMPLETED | Prediabetes; Normoglycemic |
Rousselot BVBA |
2025-01-29 | |
| NCT06273163 | TERMINATED | Obesity |
University of Texas Southwestern Medical Center |
2024-03-05 | |
| NCT05895643 | COMPLETED | Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder |
Psychiatric Centre Rigshospitalet |
2023-06-13 | PHASE2 |
| NCT06895408 | COMPLETED | Pancreatectomy; Hyperglycemia |
University Hospital, Gentofte, Copenhagen |
2025-02-19 | |
| NCT07368855 | COMPLETED | Obesity; Depression; GLP-1 |
University of California, San Diego |
2024-05-01 | |
| NCT04615910 | UNKNOWN | Diabetes Mellitus |
Radboud University Medical Center |
2021-07-01 | PHASE2 |
| NCT06621017 | COMPLETED | Obesity; Overweight |
Rose Pharma Inc |
2024-09-26 | PHASE2 |
| NCT05779644 | UNKNOWN | Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid |
RenJi Hospital |
2023-02-23 | |
| NCT06565611 | ACTIVE_NOT_RECRUITING | Obesity |
Palatin Technologies, Inc |
2024-08-05 | PHASE2 |
| NCT05078255 | COMPLETED | Type 2 Diabetes; Obesity |
Asger Lund, MD |
2022-01-27 | |
| NCT06298799 | UNKNOWN | Type 2 Diabetes; Obesity |
GENGE |
2023-10-01 | |
| NCT06057077 | UNKNOWN | Type 1 Diabetes |
Ministry of Health, Saudi Arabia |
2024-01-01 | PHASE1; PHASE2 |
| NCT05786521 | COMPLETED | Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity |
The University of Texas Health Science Center at San Antonio |
2023-04-01 | PHASE4 |
| NCT07539584 | COMPLETED | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM) |
Moscow Regional Research and Clinical Institute (MONIKI) |
2022-03-01 | |
| NCT06333496 | COMPLETED | Blood Sugar; High; Overweight and Obesity; Fat Burn; Obesity; Heart Health Markers |
Alpine Biotech LLC |
2024-01-02 | |
| NCT05417659 | COMPLETED | Energy Intake |
University of Bath |
2022-10-10 | |
| NCT06094894 | COMPLETED | GLP-1; Gut Microbiota; Insulin Resistance |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2023-06-01 | |
| NCT07491835 | COMPLETED | Obesity & Overweight; Appetite Regulation |
Queen Mary University of London |
2023-10-18 | |
| NCT05302596 | COMPLETED | Obesity; Aging |
State University of New York at Buffalo |
2022-09-01 | PHASE2 |
| NCT03115424 | COMPLETED | Obesity |
Mayo Clinic |
2017-06-22 | PHASE3 |
| NCT05037045 | COMPLETED | Type 2 Diabetes Mellitus |
The Affiliated Hospital of Xuzhou Medical University |
2019-01-10 | |
| NCT05767255 | UNKNOWN | Diabetes Mellitus, Type 2 Treated With Insulin |
Hospital Universitario San Ignacio |
2022-12-01 | PHASE3 |
| NCT02829502 | UNKNOWN | Ischemic Stroke |
Christina Kruuse |
2016-08 | PHASE2 |
| NCT03498001 | COMPLETED | Type II Diabetes |
Centre Hospitalier Universitaire Dijon |
2018-04-16 | |
| NCT04964388 | TERMINATED | Osteoporosis, Postmenopausal; Diabetes Mellitus, Type 2 |
University of Mississippi Medical Center |
2021-11-09 | PHASE2 |
| NCT05444569 | COMPLETED | Healthy |
Eli Lilly and Company |
2022-08-08 | PHASE1 |
| NCT05578352 | UNKNOWN | Type 2 Diabetes Mellitus |
Nanjing First Hospital, Nanjing Medical University |
2022-08-05 | |
| NCT04466618 | COMPLETED | Healthy; Type 2 Diabetes |
Adrian Vella |
2021-04-15 | PHASE3 |
| NCT05249881 | UNKNOWN | Diabetes Mellitus, Type 2; Weight Change, Body |
Aga Khan University |
2022-03-10 | EARLY_PHASE1 |
| NCT04504396 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
PegBio Co., Ltd. |
2020-06-23 | PHASE3 |
| NCT05446415 | UNKNOWN | Severe Obesity; Type 2 Diabetes Mellitus in Obese |
University of Sao Paulo General Hospital |
2020-02-05 | |
| NCT05154461 | COMPLETED | Healthy Adult Volunteers |
Göteborg University |
2021-12-05 | |
| NCT04459338 | COMPLETED | Healthy |
Adrian Vella |
2021-03-04 | PHASE3 |
| NCT04813146 | COMPLETED | Diabetic Neuropathies |
Riphah International University |
2021-02-05 | |
| NCT04232605 | UNKNOWN | Headache, Migraine |
Danish Headache Center |
2020-01-09 | |
| NCT02844907 | TERMINATED | Insulin Secretion |
VA Office of Research and Development |
2018-07-01 | PHASE4 |
| NCT03018665 | UNKNOWN | Diabetes Mellitus, Type 2 |
The First Hospital of Jilin University |
2017-02 | PHASE4 |
| NCT03645408 | TERMINATED | Alcohol Use Disorder |
Boston Medical Center |
2019-05-02 | PHASE1 |
| NCT03101930 | COMPLETED | Obesity; PreDiabetes |
Vanderbilt University Medical Center |
2017-05-01 | PHASE4 |
| NCT03889496 | TERMINATED | Diabetes Mellitus |
Radboud University Medical Center |
2015-11-16 | |
| NCT02550548 | COMPLETED | Insulin Secretion |
David D'Alessio, M.D. |
2016-04-21 | PHASE1 |
| NCT05290506 | COMPLETED | PreDiabetes; Type 2 Diabetes |
National University of Malaysia |
2020-08-01 | PHASE3 |
| NCT03994549 | COMPLETED | Healthy |
Zealand Pharma |
2019-06-14 | EARLY_PHASE1 |
| NCT03739268 | COMPLETED | Type 2 Diabetes Mellitus |
Steno Diabetes Center Copenhagen |
2018-09-01 | |
| NCT02617654 | COMPLETED | Type 1 Diabetes |
Per-Ola Carlsson |
2015-11 | PHASE2 |
| NCT02496611 | COMPLETED | Severe Obesity |
University of Minnesota |
2015-12 | PHASE2 |
| NCT04337268 | COMPLETED | The GLP-1-mediated Gut-kidney Axis |
Rigshospitalet, Denmark |
2019-04-01 | |
| NCT03361098 | COMPLETED | Type 2 Diabetes Mellitus; Obesity |
Amsterdam UMC, location VUmc |
2017-09-18 | PHASE4 |
| NCT03029351 | TERMINATED | Type2 Diabetes; Kidney Diseases |
University at Buffalo |
2017-01-10 | PHASE4 |
| NCT03772067 | UNKNOWN | Type2 Diabetes; Healthy Obesity, Metabolically |
Tel Aviv University |
2018-12-28 | |
| NCT01234649 | COMPLETED | Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation |
Woman's |
2011-08-11 | PHASE3 |
| NCT02535299 | UNKNOWN | GLP-1；Metformin；Telomere-telomerase System；Par-4 |
Third Military Medical University |
2016-06 | PHASE4 |
| NCT02846233 | COMPLETED | Type 2 Diabetes Mellitus |
University of California, San Francisco |
2016-08 | |
| NCT03526289 | COMPLETED | Type 2 Diabetes Mellitus; Overweight and Obesity |
University Hospital, Gentofte, Copenhagen |
2017-11-08 | |
| NCT02940184 | UNKNOWN | Physiology |
University of Copenhagen |
2016-06 | |
| NCT02302976 | COMPLETED | Cocaine Dependence |
Yale University |
2014-11 | PHASE1 |
| NCT03350191 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2017-12-20 | PHASE1 |
| NCT03081676 | COMPLETED | Maturity-Onset Diabetes of the Young, Type 3 |
University Hospital, Gentofte, Copenhagen |
2017-03-08 | |
| NCT02787551 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-07-06 | PHASE3 |
| NCT03455049 | COMPLETED | Increased Insulin |
Indonesia University |
2017-10-17 | |
| NCT02299050 | COMPLETED | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2014-06 | PHASE4 |
| NCT02954692 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-11-30 | PHASE4 |
| NCT04105608 | COMPLETED | Type-2 Diabetes |
Antonio Di Mauro |
2017-11-01 | |
| NCT01232946 | COMPLETED | Type 2 Diabetes |
Indiana University |
2012-01 | |
| NCT02686177 | COMPLETED | Type 2 Diabetes |
Assistance Publique - Hôpitaux de Paris |
2016-05-18 | PHASE4 |
| NCT03009916 | COMPLETED | Bileacid Malabsorption |
University Hospital, Gentofte, Copenhagen |
2016-03 | PHASE4 |
| NCT02287285 | COMPLETED | Type 2 Diabetes Mellitus |
Blandine Laferrere |
2014-10 | EARLY_PHASE1 |
| NCT03133741 | COMPLETED | Glucose Metabolism Disorders |
University Hospital, Gentofte, Copenhagen |
2017-03-01 | |
| NCT02537834 | COMPLETED | Type 2 Diabetes Mellitus |
Kowa Company, Ltd. |
2015-08 | PHASE4 |
| NCT02887625 | UNKNOWN | Type 2 Diabetes |
Dr. Muhammad Abdulghani |
2015-02 | |
| NCT03141632 | COMPLETED | Thirst; Water-Electrolyte Imbalance |
University Hospital, Basel, Switzerland |
2016-10-17 | PHASE2 |
| NCT02127996 | UNKNOWN | Angina Pectoris; Myocardial Infarction; Reperfusion Injury; Coronary Heart Disease |
Papworth Hospital NHS Foundation Trust |
2015-03 | PHASE2 |
| NCT03325569 | COMPLETED | Incretin Hormones in PCOS With Prediabetes |
University Medical Centre Ljubljana |
2017-02-13 | |
| NCT03502083 | COMPLETED | Coronary Stenosis; Type2 Diabetes; Angina, Stable |
Papworth Hospital NHS Foundation Trust |
2015-12-01 | |
| NCT02236299 | UNKNOWN | Right Coronary Artery Percutaneous Coronary Intervention; Right Ventricular Diastolic Dysfunction |
Papworth Hospital NHS Foundation Trust |
2014-09 | |
| NCT02718950 | UNKNOWN | Obesity; Type 2 Diabetes Mellitus |
University of Campinas, Brazil |
2016-06 | PHASE3 |
| NCT01795144 | COMPLETED | Monogenic Diabetes |
University of Chicago |
2014-01 | PHASE1 |
| NCT02767596 | TERMINATED | Diabetes Mellitus Type 2 |
Laniado Hospital |
2016-07-12 | PHASE4 |
| NCT02796950 | COMPLETED | Diabetes Mellitus Type 2 |
University of Aarhus |
2016-06 | |
| NCT02036372 | COMPLETED | Diabetes Mellitus Type II |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-01 | |
| NCT03195257 | COMPLETED | Type 1 Diabetes Mellitus |
Mikkel Christensen |
2012-11-17 | |
| NCT02550145 | TERMINATED | Hypoglycemia |
Tracey McLaughlin |
2014-02 | PHASE1 |
| NCT02745470 | COMPLETED | Diabetes Mellitus |
Seoul National University Hospital |
2016-02 | |
| NCT03680482 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Chile |
2016-01-11 | |
| NCT02598791 | COMPLETED | Obesity; Adiposity; Type 2 Diabetes |
University Hospital, Gentofte, Copenhagen |
2015-10-01 | |
| NCT01903070 | COMPLETED | Diabetes Mellitus |
Profil Institut für Stoffwechselforschung GmbH |
2013-07-11 | PHASE4 |
| NCT02082496 | COMPLETED | Obesity |
University of Copenhagen |
2014-06 | PHASE2 |
| NCT01845259 | UNKNOWN | Impaired Glucose Tolerance Associated With Drugs |
Psychiatric Centre Rigshospitalet |
2013-04 | PHASE2 |
| NCT02128022 | COMPLETED | Angina Pectoris |
Papworth Hospital NHS Foundation Trust |
2014-07 | PHASE1 |
| NCT02274740 | TERMINATED | Type II Diabetes Mellitus |
Sanofi |
2015-04 | PHASE2 |
| NCT01744236 | COMPLETED | Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2013-04 | PHASE4 |
| NCT02168491 | COMPLETED | Type 2 Diabetes Mellitus |
Medical University of Vienna |
2014-11 | PHASE3 |
| NCT02501850 | UNKNOWN | Diabetes Mellitus Type 2 |
Hospital Universitari Vall d'Hebron Research Institute |
2014-10 | PHASE4 |
| NCT01575301 | COMPLETED | Diabetes |
University of Dundee |
2011-03 | |
| NCT01794429 | COMPLETED | Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia |
Bjorn H. Ebdrup |
2013-02 | PHASE3 |
| NCT02340247 | COMPLETED | Severe Obesity |
Hvidovre University Hospital |
2014-11 | PHASE4 |
| NCT02042664 | COMPLETED | Obesity; Diabetes |
Assistance Publique Hopitaux De Marseille |
2011-01 | PHASE3 |
| NCT01934816 | TERMINATED | Healthy Subjects |
Katarina Kos |
2013-06 | |
| NCT01954147 | UNKNOWN | Type 2 Diabetes |
Diabetes Care Center of Nanjing Military Command |
2013-10 | PHASE1; PHASE2 |
| NCT02691481 | COMPLETED | Type 2 Diabetes Mellitus; Obesity |
Joslin Diabetes Center |
2014-05 | |
| NCT01677104 | COMPLETED | Type 2 Diabetes; Obesity |
Katarina Kos |
2012-08 | |
| NCT01524705 | COMPLETED | Type 2 Diabetes |
University of Washington |
2012-08 | PHASE4 |
| NCT02235584 | COMPLETED | Type 2 Diabetes |
Hvidovre University Hospital |
2009-07 | |
| NCT01988545 | UNKNOWN | Healthy |
Zealand University Hospital |
2013-11 | |
| NCT01967589 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2013-10 | PHASE1 |
| NCT02094183 | COMPLETED | Obesity |
University of Copenhagen |
2011-09 | |
| NCT01931982 | COMPLETED | Type 2 Diabetes; Microvascular Dysfunction |
Bispebjerg Hospital |
2013-05 | PHASE4 |
| NCT01977833 | UNKNOWN | Type 2 Diabetes |
Tel Aviv University |
2013-10 | |
| NCT01749163 | COMPLETED | Extra-pancreatic Incretin Effect; Glucose Effectiveness |
Rigshospitalet, Denmark |
2012-09 | |
| NCT01656057 | COMPLETED | To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion |
Filip Krag Knop |
2012-07 | |
| NCT01281228 | COMPLETED | Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity |
Amsterdam UMC, location VUmc |
2011-09 | |
| NCT01727583 | COMPLETED | Healthy |
Société des Produits Nestlé (SPN) |
2012-09 | |
| NCT01507597 | COMPLETED | Type 2 Diabetes; Type 1 Diabetes |
University Hospital, Gentofte, Copenhagen |
2011-12 | |
| NCT01452451 | COMPLETED | Diabetes Mellitus |
Hanmi Pharmaceutical Company Limited |
2011-12 | PHASE2 |
| NCT01666223 | COMPLETED | Type 2 Diabetes; Obesity |
University Hospital, Gentofte, Copenhagen |
2012-11 | |
| NCT01455441 | COMPLETED | Type 2 Diabetes |
Tina Vilsboll |
2011-10 | PHASE4 |
| NCT01686945 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2; Healthy |
Novo Nordisk A/S |
2012-09-19 | PHASE1 |
| NCT01918566 | COMPLETED | Exploratory Behavior |
University Hospital, Basel, Switzerland |
2012-03 | |
| NCT01534442 | UNKNOWN | The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration. |
University Hospital, Gentofte, Copenhagen |
2011-09 | |
| NCT01607450 | COMPLETED | Type 2 Diabetes Mellitus; Healthy |
Indiana University |
2010-05 | PHASE2; PHASE3 |
| NCT01687582 | COMPLETED | Type 2 Diabetes; Psoriasis |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2012-01 | |
| NCT01501084 | COMPLETED | Obesity |
University of California, Los Angeles |
2011-12 | PHASE1 |
| NCT01664624 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2012-07 | PHASE1 |
| NCT00856700 | COMPLETED | Metabolic Syndrome |
University of Rome Tor Vergata |
2008-11 | |
| NCT00923962 | COMPLETED | Type 2 Diabetes Mellitus |
University Hospital, Gentofte, Copenhagen |
2009-06 | |
| NCT00673894 | COMPLETED | Type 2 Diabetes |
Garvan Institute of Medical Research |
2008-04 | |
| NCT01333163 | COMPLETED | Kidney Functional |
Jeppe Skov |
2011-05 | |
| NCT01453842 | COMPLETED | Type 2 Diabetes Mellitus |
University of Copenhagen |
2011-03 | EARLY_PHASE1 |
| NCT01176760 | UNKNOWN | Vagotomy, Truncal |
University Hospital, Gentofte, Copenhagen |
2009-08 | |
| NCT01235819 | COMPLETED | Type 1 Diabetes |
Command Hospital, India |
2010-11 | PHASE4 |
| NCT03697486 | COMPLETED | PYY; Ghrelin; Appetite; Gut Hormones; Obesity; Protein Consumption |
Indonesia University |
2010-10 | |
| NCT01373450 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2011-06 | PHASE1 |
| NCT01599338 | COMPLETED | Type 2 Diabetes Mellitus; Overweight |
Centre Hospitalier Universitaire Dijon |
2011-01 | |
| NCT00869102 | WITHDRAWN | Diabetes; Metabolic Syndrome |
University Hospital Tuebingen |
2009-05 | |
| NCT00993720 | COMPLETED | Diabetes Mellitus |
Hvidovre University Hospital |
2009-10 | PHASE2; PHASE3 |
| NCT00798590 | TERMINATED | Critically Ill; Hypoglycemia |
Johns Hopkins University |
2008-12 | PHASE2 |
| NCT01043445 | COMPLETED | Type 2 Diabetes |
Glostrup University Hospital, Copenhagen |
2009-09 | |
| NCT00822705 | COMPLETED | Anti Obesity Agent |
University Hospital, Basel, Switzerland |
2008-08 | PHASE1; PHASE2 |
| NCT00822003 | COMPLETED | Glucose Homeostasis |
University Hospital, Basel, Switzerland |
2008-02 | PHASE1; PHASE2 |
| NCT00603031 | COMPLETED | Type-1 Diabetes Mellitus |
Hvidovre University Hospital |
2008-01 | |
| NCT00423501 | COMPLETED | Diabetes Mellitus Type 2 |
Hoffmann-La Roche |
2007-02 | PHASE2 |
| NCT00418288 | COMPLETED | Type 2 Diabetes; Stroke; Myocardial Infarction |
University of Aarhus |
2007-01 | |
| NCT00862589 | COMPLETED | Hyperglycemia; Hyperglucagonemia; Glucose Intolerance |
University Hospital, Gentofte, Copenhagen |
2006-10 | |
| NCT00859079 | COMPLETED | Diabetes Mellitus Type 2; Hyperglycemia |
Medical University of Graz |
2006-06 | PHASE4 |
| NCT00980083 | COMPLETED | Healthy Subjects; Gastric Emptying |
Ludwig-Maximilians - University of Munich |
2004-10 | PHASE1 |
| NCT00468884 | COMPLETED | Healthy |
University Hospital, Basel, Switzerland |
2006-10 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-06-10)
Check the
GLP-1 (7-37) Acetate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.